Overview of DA Naproxennatrium

Property	Description
Active ingredient	Naproxen Sodium
Form	Oral Tablet
Pharmacological class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use	Relief of pain, inflammation, and fever
Origin	Synthetic compound

What Type of Medicine is DA Naproxennatrium?

DA Naproxennatrium is a medicine classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), with the active ingredient being Naproxen Sodium. This classification is clinically recognized for its triple action: simultaneously reducing pain, fighting inflammation, and lowering fever. It is a synthetic compound, typically supplied as an oral tablet intended to be taken by mouth.

Naproxen belongs to the propionic acid subclass of NSAIDs and functions as a reversible cyclooxygenase (COX) inhibitor, which is key to its analgesic and anti-inflammatory effects. This status as a longer-acting NSAID means it has a more sustained effect compared to some other common pain relievers, which is a key differentiating factor in its use.

Composition and General Purpose

The active ingredient is specifically formulated as Naproxen Sodium—a salt form of Naproxen. The addition of the sodium component is a pharmaceutical design choice that helps the medicine dissolve faster once it is swallowed. This sodium salt formulation allows for a quicker onset of action than standard Naproxen.

The general therapeutic purpose of DA Naproxennatrium is to provide relief from painful and inflammatory symptoms. As an NSAID, it possesses combined analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) properties. The final benefit is comprehensive symptom relief, particularly when both pain and underlying swelling are present.

Regulatory References

FDA DailyMed entry for Naproxen Sodium

What side effects are possible with DA Naproxennatrium?

The safety profile of DA Naproxennatrium (Naproxen Sodium), a Nonsteroidal Anti-Inflammatory Drug (NSAID), is documented by regulatory bodies through specific categories of adverse reactions and safety statements.

Adverse Reaction Scope

Category	Description
Key adverse reaction categories	Gastrointestinal effects, cardiovascular thrombotic events, nervous system disturbances, renal impairment, and hypersensitivity reactions.
Frequency classification (examples)	Common reactions documented in official sources include dyspepsia, headache, nausea, and dizziness. Rare reactions include gastrointestinal bleeding, ulceration, and severe cutaneous adverse reactions.
System-organ classes involved	Gastrointestinal Disorders, Nervous System Disorders, Cardiac Disorders, Vascular Disorders, Renal and Urinary Disorders, and Skin and Subcutaneous Tissue Disorders.
Serious adverse reactions	Official warnings highlight the potential for serious cardiovascular thrombotic events (such as myocardial infarction and stroke) and serious gastrointestinal events (bleeding, ulceration, and perforation), which may be fatal. Potentially fatal severe cutaneous adverse reactions are also documented.
Population-specific safety considerations	Older adults are documented to have a greater risk for serious gastrointestinal events. Patients with pre-existing heart failure or renal/hepatic impairment are identified as requiring careful consideration. The drug's use is contraindicated starting at 30 weeks of pregnancy due to risk to the fetus.
Dose- or exposure-related patterns	The risk of serious cardiovascular events may increase with the duration of use. Serious gastrointestinal events are noted to occur at any time during use.
Safety-related restrictions or limitations	Use is contraindicated for the management of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. It is also restricted in patients with a history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs.

Regulatory Safety Summary

The official safety information structures the understanding of risks by categorizing them into frequent, generally less severe events and rare, serious events that require mandated warnings. This regulatory framework emphasizes that the potential for serious adverse reactions, particularly affecting the cardiovascular and gastrointestinal systems, is a critical characteristic associated with the entire NSAID class, and that these risks are influenced by both the duration of use and patient-specific factors.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes a range of clinical signs associated with Naproxen Sodium (DA Naproxennatrium) overdose, necessitating immediate emergency attention upon suspicion.

Feature	Official Regulatory Statement
Documented overdose presentations	Manifestations include gastrointestinal disturbances (nausea, vomiting, abdominal pain) and central nervous system effects (drowsiness, dizziness, severe headache, confusion). Other documented signs are tinnitus and blurred vision.
Physiological systems affected (as stated in label)	Adverse effects may involve the Gastrointestinal system (bleeding), Central Nervous System (seizures, coma), Renal system (acute renal failure), and result in metabolic acidosis.
Population-specific overdose notes	Increased severity or risk is officially noted in patients with impaired renal function and liver dysfunction. The elderly population is also noted as having an altered pharmacokinetic profile that may be relevant in overdose.

Overdose Classifications and Emergency Action

Classification	Official Regulatory Statement
Severity classification	Symptoms range from the common manifestations listed above to rare, life-threatening outcomes such as seizures, coma, and acute renal failure.
When immediate medical help is required	It is required to get medical help right away and to call the local emergency number or contact a Poison Control Center immediately upon suspected overdose.
Overdose-context constraints	No specific antidote is known for Naproxen Sodium. Management is based on symptomatic and supportive treatment, including the use of activated charcoal and continuous monitoring of vital signs (e.g., ECG, blood tests) to stabilize the patient.

Therapeutic Uses of DA Naproxennatrium

What DA Naproxennatrium Treats: Main Uses and Benefits

DA Naproxennatrium is applied across therapeutic domains that involve specific recurrent or episodic manifestations and conditions characterized by periods of heightened symptoms. It helps address symptom clusters that may become intense or disruptive, such as the pain, stiffness, and joint swelling associated with chronic inflammatory conditions like rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is commonly used to help with the reduction of elevated body fever and is also relevant when supportive symptom management is appropriate for acute, localized discomfort. Typical clinical scenarios include relief for pain following sprains and strains, managing symptoms of acute gout flare-ups, and addressing the intense, episodic pain of Primary Dysmenorrhea (menstrual cramps) and acute migraine attacks.

It provides support that helps ease the overall symptom burden by contributing to improved comfort during symptomatic periods. The medication may support the patient during difficult episodes by helping to ease distress.

Quick Fact: Used for Symptoms Associated with Inflammatory States DA Naproxennatrium is applied in scenarios where symptoms are linked to both pain and underlying inflammatory or irritative states, and may provide combined support to manage discomfort and swelling.

Regulatory References

Naproxen: MedlinePlus Drug Information

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility criteria for DA Naproxennatrium (Naproxen Sodium), as defined by governmental regulatory authorities.

Contraindicated Populations (Must Not Use)

Use is contraindicated for patients with:

A known allergic reaction or hypersensitivity to naproxen, aspirin, or other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).
Severe heart, kidney ( CrCl < 30 mL/min), or liver impairment.
Active gastrointestinal (GI) bleeding, perforation, or a history of recurrent peptic ulcers.
The period surrounding Coronary Artery Bypass Graft (CABG) surgery.
Pregnancy, specifically the third trimester (starting at 30 weeks gestation).

Eligibility-Related Restrictions and Cautions

Pediatric Use: Safety and efficacy are generally not established for children under two years of age. Prescription use for specific conditions is permitted in older children.
Older Adults: Use requires caution, as they are at an increased risk of serious GI side effects and may be more sensitive to the drug's effects. The lowest effective dose should be used.
Pregnancy and Lactation: Use is advised against during the third trimester. Use in the first and second trimesters, as well as while breastfeeding, requires careful medical consideration and is generally discouraged.

What should I know about interactions with other medicines?

DA Naproxennatrium Interactions with other medicines and products

DA Naproxennatrium has officially documented interaction patterns primarily involving pharmacodynamic enhancement of bleeding risk and pharmacokinetic alterations of co-administered medicines.

Interaction Class	Interacting Agents	Official Outcome (Summary)
Pharmacodynamic Risk	Anticoagulants (Warfarin), SSRIs, Oral Corticosteroids	Enhanced risk of gastrointestinal bleeding or ulceration.
Diminished Efficacy	ACE Inhibitors, ARBs, Diuretics	May reduce the therapeutic effect of these agents (e.g., lower blood pressure control).
Exposure Modification	Methotrexate, Lithium, Digoxin, Probenecid	Leads to elevated plasma levels of the co-administered drug (e.g., Methotrexate, Lithium) or Naproxen itself (with Probenecid).

The official prescribing information classifies use immediately before or after Coronary Artery Bypass Graft (CABG) surgery as strictly contraindicated. A mandatory timing rule requires that DA Naproxennatrium must not be administered for 8–12 days following Mifepristone administration. Concomitant use with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is not recommended. Furthermore, chronic consumption of three or more alcoholic drinks daily is noted as increasing the risk of serious gastrointestinal bleeding. For individuals who are elderly, volume-depleted, or have renal impairment, the interaction with ACE Inhibitors or ARBs may result in a deterioration of renal function. These documented interactions define the necessary constraints for its co-administration with other products.

Mechanism of Action

Naproxen Sodium initiates its action by influencing specific enzymatic systems involved in biochemical signaling pathways. The mechanism involves modulating the synthesis of chemical mediators, thereby influencing pathways related to localized tissue response and peripheral nerve sensitization.

Controlling the Cyclooxygenase Enzyme Cascade

The drug acts as a reversible non-selective inhibitor of the Cyclooxygenase (COX) enzymes, which are responsible for converting Arachidonic Acid into various prostaglandins. By suppressing the activity of both the constitutive COX-1 and inducible COX-2 isoforms, the drug initiates a molecular cascade that prevents the overproduction of these mediators. The action targets an initial enzymatic step within a cascade that influences multiple downstream physiological responses.

Modulating Nerve and Temperature Sensitivity

A consequence of COX inhibition is the functional desensitization of two relevant physiological systems: peripheral nociceptors (pain-sensing nerves) and the hypothalamic thermoregulatory center. By reducing the availability of sensitizing Prostaglandin E2 ( PGE2), the drug raises the stimulus threshold required to trigger a pain signal, and simultaneously helps the hypothalamus restore the body's core temperature set-point. This action modulates the signaling dynamics that influence peripheral nerve excitation and central temperature control.

Acceleration of Target Access

The specific formulation of the active ingredient as a Sodium salt is a mechanistic enabler. The sodium component allows for significantly faster dissolution and absorption, ensuring that the concentration required to inhibit the COX enzymes is achieved more rapidly in the bloodstream. This acceleration contributes to the rapid saturation of the biological target and subsequent initiation of the mechanism.

Dosage and Administration Information

DA Naproxennatrium is administered exclusively via the oral route as a tablet. The tablet should be swallowed whole with a sufficient quantity of fluid, such as water. To address potential gastric discomfort, the tablet may be taken with food or milk, though this may impact the time to onset of action. Delayed-release or enteric-coated forms must not be crushed or chewed to maintain their proper release profile.

The administration schedule is patterned according to the duration of use. For long-term management of chronic conditions, the drug is typically administered in divided doses twice daily (BID). For short-term, acute episodes of pain, the medication is used on an intermittent or as-needed basis.

The standard maximum daily dose for chronic maintenance is typically 1100 mg of naproxen sodium. While an initial higher dose of up to 1375 mg may be utilized on the first day of an acute course, this limit generally reverts to the 1100 mg maximum thereafter. Dose reduction is indicated for specific populations; in older adults and individuals with hepatic or renal impairment, therapy is initiated at the lowest effective dose. The prescribed daily amount must not be exceeded under any circumstances.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Research on DA Naproxennatrium (naproxen sodium), a non-steroidal anti-inflammatory drug (NSAID), continues to focus on its efficacy and tolerability across different acute and chronic pain conditions.

Efficacy in Acute Pain Management

Controlled clinical trials, including systematic reviews, have explored the effects of single-dose oral naproxen sodium on acute postoperative pain in adults. Findings indicate that doses equivalent to naproxen 400 mg and 500 mg were associated with meaningful levels of pain relief over four to six hours compared to placebo. The median time to the need for additional rescue medication was reported to be significantly longer for naproxen sodium compared to placebo. Studies have also investigated naproxen sodium for other acute pain types, such as migraine headache and dental pain, observing a reduction in pain intensity.

Comparative Safety and Tolerability Data

Safety data collected from clinical trials and post-marketing surveillance are essential for understanding the drug's tolerability. Research has compared the incidence of adverse events with naproxen to that of other common analgesics (like ibuprofen and acetaminophen) and placebo in short-term use. Findings suggest that the incidence of adverse events for short-term, non-prescription doses of naproxen sodium closely resembled that of placebo. The most frequently reported adverse events are often related to the gastrointestinal system, such as dyspepsia (indigestion) and abdominal discomfort.

Naproxen is associated with a lower cardiovascular (CV) risk compared to some other NSAIDs, an important consideration in the drug's overall safety profile, although all NSAIDs carry warnings regarding potential CV and gastrointestinal risks. Specific studies have also evaluated the long-term tolerability of naproxen sodium when used in fixed-dose combination therapies with other agents, such as those intended to protect the gastrointestinal lining.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about DA Naproxennatrium (FAQ)

Q: How long does it typically take for DA Naproxennatrium to start working?

A: Studies and official pharmacokinetic data indicate that this medication is designed for rapid action. The specific sodium salt formulation allows for quick absorption, and it typically reaches the necessary concentration in the bloodstream to begin its main effect within one to two hours after being administered.

Q: Is it safe to take DA Naproxennatrium if I have high blood pressure?

A: Official warnings note that nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with modest increases in blood pressure and could potentially worsen pre-existing high blood pressure. Additionally, this medicine may interfere with the effectiveness of certain blood pressure medications. The consideration of use in individuals with high blood pressure is a matter for consultation with a healthcare provider.

Q: Can I take DA Naproxennatrium if I have kidney problems?

A: Use is contraindicated (must not be used) for patients with severe kidney impairment. For individuals with less severe kidney function impairment, regulatory guidance suggests the drug should be used with caution, and generally at the lowest effective dose, due to the potential risk of worsening kidney function.

Q: Does DA Naproxennatrium interact with blood thinners?

A: Yes, official documents describe a documented drug interaction. Taking this medication with anticoagulants (blood thinners), such as warfarin, or with antiplatelet agents, significantly increases the risk of serious gastrointestinal bleeding or ulceration.

Q: Can I use DA Naproxennatrium if I am pregnant or breastfeeding?

A: The drug is contraindicated (not allowed) starting at 20 weeks of pregnancy and throughout the third trimester because of risks to the fetus. Use during the first and second trimesters, as well as while breastfeeding, is generally advised against. The decision for use in these circumstances requires careful medical consideration, as advised by regulatory information.

Q: Is DA Naproxennatrium safe if I have a history of heart attack or stroke?

A: Official warnings state that all NSAIDs carry a risk of increasing the chance of a serious cardiovascular event, such as a heart attack or stroke. This risk is generally increased in people with existing heart disease or a history of these events. For individuals with a history of heart attack or stroke, consultation with a healthcare provider is strongly advised prior to use.

Q: Why is DA Naproxennatrium sometimes prescribed for gout?

A: Regulatory agencies have officially indicated this medicine for the treatment of certain painful and inflammatory conditions, including the acute flare-ups of gout (gouty arthritis).

Q: Does DA Naproxennatrium cause sleepiness or drowsiness?

A: The official list of documented adverse reactions includes drowsiness (somnolence) and fatigue as potential effects. Due to the possibility of these effects, caution is warranted when engaging in activities such as driving or operating machinery.

Q: What common over-the-counter medications should I avoid while taking DA Naproxennatrium?

A: Official warnings strongly advise against taking this medication with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which includes common over-the-counter products such as ibuprofen or high-dose aspirin. Combining these products significantly increases the risk of serious gastrointestinal side effects.

Q: Are there any long-term side effects associated with taking DA Naproxennatrium?

A: Official safety information notes that the risk of serious adverse events, particularly those affecting the cardiovascular and gastrointestinal systems (such as internal bleeding or ulcers), may increase with the duration of use of the medication. Therefore, continuous use should be reviewed regularly by a healthcare professional.

Q: How long does the pain relief from DA Naproxennatrium usually last?

A: Official data indicates that this medication has a long half-life, meaning the pain-relieving effect of a single dose typically lasts for an extended period, generally up to 12 hours.

Q: Are there specific food items or drinks to avoid while using DA Naproxennatrium?

A: Official warnings specifically state that the chronic consumption of three or more alcoholic drinks daily is noted as increasing the risk of serious gastrointestinal bleeding when combined with this medication.

Q: What are the signs of an allergic reaction to DA Naproxennatrium?

A: Official drug labels list signs of a serious allergic reaction (hypersensitivity) which may include difficulty breathing (asthma or wheezing), swelling of the face or throat, hives, a severe rash, or blisters. The appearance of these signs is considered a medical emergency and necessitates immediate care.

Q: Can DA Naproxennatrium be used for menstrual cramps?

A: Yes, regulatory agencies have officially indicated this medicine for the treatment of primary dysmenorrhea, which is the medical term for menstrual cramps.

Q: Is DA Naproxennatrium safe for people with asthma?

A: Use is contraindicated if there is a history of allergic-type reactions (such as asthma or hives) after taking aspirin or other NSAIDs. For patients with pre-existing asthma without known sensitivity, official warnings advise caution, as NSAIDs have the potential to worsen asthma symptoms.

Q: Is there a maximum duration for how long DA Naproxennatrium can be used continuously?

A: While the drug is indicated for the long-term management of chronic conditions, regulatory guidelines emphasize that continuous use should be regularly reviewed. Some higher daily dose ranges are explicitly restricted to limited periods, often up to six months, highlighting the importance of using the shortest possible duration.

Q: Can DA Naproxennatrium affect my ability to drive or operate machinery?

A: Official warnings note that engaging in activities such as driving or operating machinery may be impaired. This is because the medication may cause adverse effects like dizziness, drowsiness, headache, or vision changes.

Q: What is the purpose of the 'sodium' part in Naproxennatrium?

A: The active ingredient is chemically formulated as a sodium salt to enhance its solubility. This pharmaceutical design choice is intended to help the medicine dissolve faster once swallowed, which contributes to a quicker onset of its effect.

Q: Are children allowed to take DA Naproxennatrium?

A: Safety and effectiveness are generally not established for children under two years of age. For children older than two, prescription use is officially allowed for specific conditions, such as juvenile idiopathic arthritis, using age-appropriate or weight-based dosing.

Q: What common skin reactions, if any, are associated with DA Naproxennatrium?

A: The official adverse reaction list includes skin changes such as rash and itching as potential side effects. There are also official warnings about the rare possibility of severe skin reactions.

Q: How should DA Naproxennatrium be stored?

A: Official guidelines state that the medication should be stored at Controlled Room Temperature (typically 20 C to 25 C), protected from excessive heat and high humidity. It must also be kept in its original, well-closed container, out of the sight and reach of children.

Q: Why do some people experience ringing in the ears (tinnitus) with DA Naproxennatrium?

A: Official adverse event lists document tinnitus (ringing or buzzing in the ears) as a potential side effect associated with the use of this drug, though its exact mechanism is not fully detailed in the patient label.

Q: Is DA Naproxennatrium used for chronic pain management?

A: Yes, official indications state that the drug is used for the long-term management of chronic conditions, such as certain types of arthritis, which involves providing continuous relief for associated chronic pain and inflammation.

Q: How is DA Naproxennatrium different from Celecoxib (Celebrex)?

A: Official pharmacological classifications show a key difference in their mechanism of action. DA Naproxennatrium is a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, affecting both COX-1 and COX-2, while Celecoxib is officially classified as a selective COX-2 inhibitor.

Q: Does DA Naproxennatrium interfere with the effectiveness of blood pressure medication?

A: Official drug interaction lists indicate that the drug may reduce the therapeutic effect of certain blood pressure medications, such as ACE inhibitors and ARBs, meaning it may make them less effective at lowering blood pressure.

Q: Can DA Naproxennatrium cause an increase in liver enzymes?

A: Official data indicates that elevations in serum aminotransferase levels (which are measures of liver enzymes) have been documented in a percentage of patients, particularly those receiving prolonged courses of this drug.

Q: Are there specific patient groups that should use DA Naproxennatrium with extra caution?

A: Official warnings highlight several groups that require extra caution. These include older adults, those with pre-existing conditions like heart failure, high blood pressure, or impairment of kidney or liver function, and individuals with a history of gastrointestinal bleeding.

How should DA Naproxennatrium be stored and disposed of?

Official Storage and Disposal Requirements

DA Naproxennatrium (Naproxen Sodium tablets) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excessive heat and high humidity, and storage conditions must strictly avoid freezing. Do not store the medicine above 40 C (104 F).

Tablets should be kept in a well-closed container and must be stored out of the sight and reach of children to ensure safety. For disposal, unused or expired medicine must be discarded according to local regulatory requirements. It is mandatory to avoid disposing of the product in household waste or via wastewater.

DA Naproxennatrium